J Korean Neurosurg Soc.  2015 Jun;57(6):408-414. 10.3340/jkns.2015.57.6.408.

Moyamoya Syndrome: A Window of Moyamoya Disease

• Phi JH
• Wang KC
• Lee JY
• Kim SK

• KMID: 2191246
• DOI: http://doi.org/10.3340/jkns.2015.57.6.408

Abstract

Moyamoya-like vasculopathy develops in association with various systemic diseases and conditions, which is termed moyamoya syndrome. Relatively common diseases and conditions are related to moyamoya syndrome, including neurofibromatosis type 1, Down syndrome, thyroid disease, and cranial irradiation. Moyamoya syndrome shares phenotypical characteristics with idiopathic moyamoya disease. However, they differ in other details, including clinical presentations, natural history, and treatment considerations. The study of moyamoya syndrome can provide clinicians and researchers with valuable knowledge and insight. Although it is infrequently encountered in clinical practice, moyamoya-like vasculopathy can severely complicate outcomes for patients with various underlying diseases when the clinician fails to expect or diagnose moyamoya syndrome development. Furthermore, moyamoya syndrome could be used as a doorway to more enigmatic moyamoya disease in research. More comprehensive survey and investigation are required to uncover the secrets of all the moyamoya-like phenomena.

Keyword

Moyamoya syndrome; Neurofibromatosis; Down syndrome; Thyroid disease; Radiation

MeSH Terms

Cranial Irradiation
Down Syndrome
Humans
Moyamoya Disease*
Natural History
Neurofibromatoses
Neurofibromatosis 1
Thyroid Diseases

Figure

• 

  Fig. 1 Images of a boy with neurofibromatosis type 1. A : Magnetic resonance image (MRI) taken at age 7 revealed a thickened optic chiasm with gadolinium enhancement, suggesting the presence of an optic glioma. The boy experienced symptomatic progression of the optic glioma and received cranial irradiation (50.4 Gy) for treatment at age 9. B : Magnetic resonance angiography (MRA) was taken 4 years after the radiation therapy. Note the luminal narrowing of bilateral middle cerebral arteries (right side more severe) and the invisible horizontal portion of the right anterior cerebral artery. C : A markedly decreased vascular reserve in the right hemisphere was shown after infusion of diamox in single photon emission computed tomography. D : A delayed time-to-peak in the right hemisphere was also observed in a perfusion MRI. At that time, the patient was asymptomatic and no treatment was recommended. One year later, the patient began to complain of morning headaches, with increasing intensity over time. Encephaloduroarteriosynangiosis was performed on the right side. After surgery, the patient was free of headaches.

• 

  Fig. 2 A 9-year-old girl with Down syndrome had recurrent vomiting for 2 years. Examination of gastrointestinal system revealed no causes of the vomiting. A : A brain magnetic resonance image (MRI) was taken and an old small infarction was found in the left anterior watershed zone. The left middle cerebral artery trunk was invisible (not shown). B : A delayed time-to-peak in the left middle cerebral artery territory was observed in perfusion MRI. C and D : A subsequent angiography revealed a normal-looking right internal carotid artery and a near occlusion of left distal internal carotid artery with minute collateral vessel formation. Moyamoya syndrome was diagnosed. Although it was unclear that her vomiting was related to the cerebral vasculopathy, a pre-existing infarction warranted a surgical intervention. Encephaloduroarteriosynangiosis was performed on the left side. After surgery, her vomiting frequency decreased significantly. This patient illustrates the difficulty in evaluating neurological symptoms in Down syndrome patients.

Reference

1. Bajaj A, Li QF, Zheng Q, Pumiglia K. Loss of NF1 expression in human endothelial cells promotes autonomous proliferation and altered vascular morphogenesis. PLoS One. 2012; 7:e49222. PMID: 23145129.

2. Berk AT, Saatci AO, Erçal MD, Tunç M, Ergin M. Ocular findings in 55 patients with Down's syndrome. Ophthalmic Genet. 1996; 17:15–19. PMID: 8740693.

3. Booth F, Yanofsky R, Ross IB, Lawrence P, Oen K. Primary antiphospholipid syndrome with moyamoya-like vascular changes. Pediatr Neurosurg. 1999; 31:45–48. PMID: 10545822.

4. Bowers DC, Liu Y, Leisenring W, McNeil E, Stovall M, Gurney JG, et al. Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors : a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2006; 24:5277–5282. PMID: 17088567.

5. Cairns AG, North KN. Cerebrovascular dysplasia in neurofibromatosis type 1. J Neurol Neurosurg Psychiatry. 2008; 79:1165–1170. PMID: 18469031.

6. Chiang CS, Hong JH, Stalder A, Sun JR, Withers HR, McBride WH. Delayed molecular responses to brain irradiation. Int J Radiat Biol. 1997; 72:45–53. PMID: 9246193.

7. Czarkowski M, Hilgertner L, Powałowski T, Radomski D. The stiffness of the common carotid artery in patients with Graves' disease. Int Angiol. 2002; 21:152–157. PMID: 12110776.

8. Desai SS, Paulino AC, Mai WY, Teh BS. Radiation-induced moyamoya syndrome. Int J Radiat Oncol Biol Phys. 2006; 65:1222–1227. PMID: 16626890.

9. Fajardo LF. The pathology of ionizing radiation as defined by morphologic patterns. Acta Oncol. 2005; 44:13–22. PMID: 15848902.

10. Franklyn JA, Boelaert K. Thyrotoxicosis. Lancet. 2012; 379:1155–1166. PMID: 22394559.

11. Fulcher T, Griffin M, Crowley S, Firth R, Acheson R, O'Meara N. Diabetic retinopathy in Down's syndrome. Br J Ophthalmol. 1998; 82:407–409. PMID: 9640190.

12. Ghosh PS, Rothner AD, Emch TM, Friedman NR, Moodley M. Cerebral vasculopathy in children with neurofibromatosis type 1. J Child Neurol. 2013; 28:95–101. PMID: 22532547.

13. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet. 2000; 355:165–169. PMID: 10675114.

14. Ikeda H, Sasaki T, Yoshimoto T, Fukui M, Arinami T. Mapping of a familial moyamoya disease gene to chromosome 3p24.2-p26. Am J Hum Genet. 1999; 64:533–537. PMID: 9973290.

15. Im SH, Oh CW, Kwon OK, Kim JE, Han DH. Moyamoya disease associated with Graves disease : special considerations regarding clinical significance and management. J Neurosurg. 2005; 102:1013–1017. PMID: 16028759.

16. Inoue TK, Ikezaki K, Sasazuki T, Matsushima T, Fukui M. Linkage analysis of moyamoya disease on chromosome 6. J Child Neurol. 2000; 15:179–182. PMID: 10757474.

17. Jacks T, Shih TS, Schmitt EM, Bronson RT, Bernards A, Weinberg RA. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet. 1994; 7:353–361. PMID: 7920653.

18. Jea A, Smith ER, Robertson R, Scott RM. Moyamoya syndrome associated with Down syndrome : outcome after surgical revascularization. Pediatrics. 2005; 116:e694–e701. PMID: 16263984.

19. Jeong HC, Kim YJ, Yoon W, Joo SP, Lee SS, Park YW. Moyamoya syndrome associated with systemic lupus erythematosus. Lupus. 2008; 17:679–682. PMID: 18625642.

20. Jett K, Friedman JM. Clinical and genetic aspects of neurofibromatosis 1. Genet Med. 2010; 12:1–11. PMID: 20027112.

21. Kainth DS, Chaudhry SA, Kainth HS, Suri FK, Qureshi AI. Prevalence and characteristics of concurrent down syndrome in patients with moyamoya disease. Neurosurgery. 2013; 72:210–215. discussion 215PMID: 23149966.

22. Kamada F, Aoki Y, Narisawa A, Abe Y, Komatsuzaki S, Kikuchi A, et al. A genome-wide association study identifies RNF213 as the first Moyamoya disease gene. J Hum Genet. 2011; 56:34–40. PMID: 21048783.

23. Keene DL, Johnston DL, Grimard L, Michaud J, Vassilyadi M, Ventureyra E. Vascular complications of cranial radiation. Childs Nerv Syst. 2006; 22:547–555. PMID: 16607532.

24. Kim SJ, Heo KG, Shin HY, Bang OY, Kim GM, Chung CS, et al. Association of thyroid autoantibodies with moyamoya-type cerebrovascular disease : a prospective study. Stroke. 2010; 41:173–176. PMID: 19926842.

25. Kim SK, Cho BK, Phi JH, Lee JY, Chae JH, Kim KJ, et al. Pediatric moyamoya disease : an analysis of 410 consecutive cases. Ann Neurol. 2010; 68:92–101. PMID: 20582955.

26. Koss M, Scott RM, Irons MB, Smith ER, Ullrich NJ. Moyamoya syndrome associated with neurofibromatosis Type 1 : perioperative and long-term outcome after surgical revascularization. J Neurosurg Pediatr. 2013; 11:417–425. PMID: 23373626.

27. Kuroda S, Houkin K. Moyamoya disease : current concepts and future perspectives. Lancet Neurol. 2008; 7:1056–1066. PMID: 18940695.

28. Lee HS, Seol HJ, Kong DS, Shin HJ. Moyamoya syndrome precipitated by cranial irradiation for craniopharyngioma in children. J Korean Neurosurg Soc. 2011; 50:535–537. PMID: 22323944.

29. Leno C, Mateo I, Cid C, Berciano J, Sedano C. Autoimmunity in Down's syndrome : another possible mechanism of Moyamoya disease. Stroke. 1998; 29:868–869. PMID: 9550527.

30. Malav IC, Kothari SS. Renal artery stenosis due to neurofibromatosis. Ann Pediatr Cardiol. 2009; 2:167–169. PMID: 20808634.

31. Mineharu Y, Liu W, Inoue K, Matsuura N, Inoue S, Takenaka K, et al. Autosomal dominant moyamoya disease maps to chromosome 17q25.3. Neurology. 2008; 70(24 Pt 2):2357–2363. PMID: 18463369.

32. Miyatake S, Miyake N, Touho H, Nishimura-Tadaki A, Kondo Y, Okada I, et al. Homozygous c.14576G>A variant of RNF213 predicts early-onset and severe form of moyamoya disease. Neurology. 2012; 78:803–810. PMID: 22377813.

33. Morris B, Partap S, Yeom K, Gibbs IC, Fisher PG, King AA. Cerebrovascular disease in childhood cancer survivors : a Children's Oncology Group Report. Neurology. 2009; 73:1906–1913. PMID: 19812380.

34. Norton KK, Xu J, Gutmann DH. Expression of the neurofibromatosis I gene product, neurofibromin, in blood vessel endothelial cells and smooth muscle. Neurobiol Dis. 1995; 2:13–21. PMID: 8980005.

35. Ohba S, Nakagawa T, Murakami H. Concurrent Graves' disease and intracranial arterial stenosis/occlusion : special considerations regarding the state of thyroid function, etiology, and treatment. Neurosurg Rev. 2011; 34:297–304. discussion 304PMID: 21424208.

36. Panegyres PK, Morris JG, O'Neill PJ, Balleine R. Moyamoya-like disease with inflammation. Eur Neurol. 1993; 33:260–263. PMID: 8467851.

37. Parsa CF, Almer Z. Supranumerary optic disc vessels may indicate reduced systemic angiogenesis in Down syndrome. Br J Ophthalmol. 2008; 92:432–433. PMID: 18303173.

38. Ram G, Chinen J. Infections and immunodeficiency in Down syndrome. Clin Exp Immunol. 2011; 164:9–16. PMID: 21352207.

39. Rea D, Brandsema JF, Armstrong D, Parkin PC, deVeber G, MacGregor D, et al. Cerebral arteriopathy in children with neurofibromatosis type 1. Pediatrics. 2009; 124:e476–e483. PMID: 19706560.

40. Rosser TL, Vezina G, Packer RJ. Cerebrovascular abnormalities in a population of children with neurofibromatosis type 1. Neurology. 2005; 64:553–555. PMID: 15699396.

41. Scott RM, Smith ER. Moyamoya disease and moyamoya syndrome. N Engl J Med. 2009; 360:1226–1237. PMID: 19297575.

42. Seol HJ, Shin DC, Kim YS, Shim EB, Kim SK, Cho BK, et al. Computational analysis of hemodynamics using a two-dimensional model in moyamoya disease. J Neurosurg Pediatr. 2010; 5:297–301. PMID: 20192649.

43. Shanahan P, Hutchinson M, Bohan A, O'Donoghue D, Sheahan K, Owens A. Hemichorea, moya-moya, and ulcerative colitis. Mov Disord. 2001; 16:570–572. PMID: 11391762.

44. Smith ER, Scott RM. Moyamoya : epidemiology, presentation, and diagnosis. Neurosurg Clin N Am. 2010; 21:543–551. PMID: 20561502.

45. Sobata E, Ohkuma H, Suzuki S. Cerebrovascular disorders associated with von Recklinghausen's neurofibromatosis : a case report. Neurosurgery. 1988; 22:544–549. PMID: 3129670.

46. Suzuki S, Mitsuyama T, Horiba A, Fukushima S, Hashimoto N, Kawamata T. Moyamoya disease complicated by Graves' disease and type 2 diabetes mellitus : report of two cases. Clin Neurol Neurosurg. 2011; 113:325–329. PMID: 21215511.

47. Tanigawara T, Yamada H, Sakai N, Andoh T, Deguchi K, Iwamura M. Studies on cytomegalovirus and Epstein-Barr virus infection in moyamoya disease. Clin Neurol Neurosurg. 1997; 99(Suppl 2):S225–S228. PMID: 9409443.

48. Ullrich NJ, Robertson R, Kinnamon DD, Scott RM, Kieran MW, Turner CD, et al. Moyamoya following cranial irradiation for primary brain tumors in children. Neurology. 2007; 68:932–938. PMID: 17372129.

49. Vis JC, Duffels MG, Winter MM, Weijerman ME, Cobben JM, Huisman SA, et al. Down syndrome : a cardiovascular perspective. J Intellect Disabil Res. 2009; 53:419–425. PMID: 19228275.

50. Williams VC, Lucas J, Babcock MA, Gutmann DH, Korf B, Maria BL. Neurofibromatosis type 1 revisited. Pediatrics. 2009; 123:124–133. PMID: 19117870.

51. Xu J, Ismat FA, Wang T, Yang J, Epstein JA. NF1 regulates a Ras-dependent vascular smooth muscle proliferative injury response. Circulation. 2007; 116:2148–2156. PMID: 17967772.

52. Yamada H, Deguchi K, Tanigawara T, Takenaka K, Nishimura Y, Shinoda J, et al. The relationship between moyamoya disease and bacterial infection. Clin Neurol Neurosurg. 1997; 99(Suppl 2):S221–S224. PMID: 9409442.

53. Yamauchi T, Tada M, Houkin K, Tanaka T, Nakamura Y, Kuroda S, et al. Linkage of familial moyamoya disease (spontaneous occlusion of the circle of Willis) to chromosome 17q25. Stroke. 2000; 31:930–935. PMID: 10754001.

54. Yonekawa Y, Ogata N, Kaku Y, Taub E, Imhof HG. Moyamoya disease in Europe, past and present status. Clin Neurol Neurosurg. 99(Suppl 2):1997; S58–S60. PMID: 9409407.